Profil

Pescatore Pierre

See author's contact details
Main Referenced Co-authors
Belaiche, Jacques  (4)
De Vos, M. (4)
Fiasse, R. (4)
Louis, Edouard  (4)
Pelckmans, P. (4)
Main Referenced Keywords
Crohn disease (1); genetics (1); infliximab (1); tumour necrosis factor (1);
Main Referenced Disciplines
Gastroenterology & hepatology (4)
Rheumatology (1)

Publications (total 4)

The most downloaded
644 downloads
Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., Malaise, M., & Belaiche, J. (July 2002). A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 37 (7), 818-824. doi:10.1080/713786515 https://hdl.handle.net/2268/27766

The most cited

270 citations (Scopus®)

Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., Malaise, M., & Belaiche, J. (July 2002). A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 37 (7), 818-824. doi:10.1080/713786515 https://hdl.handle.net/2268/27766

Vermeire, S., Louis, E., Carbonez, A., Van Assche, G., Noman, M., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., & Rutgeerts, P. (September 2002). Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. American Journal of Gastroenterology, 97 (9), 2357-2363. doi:10.1111/j.1572-0241.2002.05991.x
Peer Reviewed verified by ORBi

Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., Malaise, M., & Belaiche, J. (July 2002). A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 37 (7), 818-824. doi:10.1080/713786515
Peer Reviewed verified by ORBi

Vermeire, S., Louis, E., Rutgeerts, P., De Vos, M., Van Gossum, A., Belaiche, J., Pescatore, P., Fiasse, R., Pelckmans, P., Vlietinck, R., Merlin, F., Zouali, H., Thomas, G., Colombel, J. F., & Hugot, J. P. (July 2002). NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 123 (1), 106-111. doi:10.1053/gast.2002.34172
Peer Reviewed verified by ORBi

Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., Poulain, D., Bossuyt, X., & Rutgeerts, P. (June 2002). Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. American Journal of Gastroenterology, 97 (6), 1458-1462. doi:10.1111/j.1572-0241.2002.05689.x
Peer Reviewed verified by ORBi

Contact ORBi